Swedbank AB Has $5.90 Million Holdings in InMode Ltd. (NASDAQ:INMD)

Swedbank AB decreased its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 57.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 348,000 shares of the healthcare company's stock after selling 468,000 shares during the quarter. Swedbank AB owned 0.41% of InMode worth $5,899,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of INMD. Carmel Capital Partners LLC lifted its stake in InMode by 6.9% in the 3rd quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company's stock valued at $195,000 after buying an additional 741 shares in the last quarter. Meritage Portfolio Management boosted its stake in shares of InMode by 9.5% during the 3rd quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company's stock worth $250,000 after purchasing an additional 1,284 shares during the last quarter. Cetera Advisors LLC grew its holdings in shares of InMode by 8.9% during the first quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company's stock worth $368,000 after buying an additional 1,394 shares in the last quarter. Inspire Advisors LLC raised its position in shares of InMode by 9.0% in the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company's stock valued at $391,000 after buying an additional 1,778 shares during the last quarter. Finally, Asset Dedication LLC acquired a new position in shares of InMode in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 68.04% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on INMD. Barclays lowered their target price on shares of InMode from $29.00 to $27.00 and set an "overweight" rating for the company in a research note on Monday, October 14th. BTIG Research started coverage on InMode in a report on Thursday, October 17th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of InMode in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, InMode currently has a consensus rating of "Hold" and a consensus target price of $22.60.

InMode Price Performance

Shares of NASDAQ:INMD traded up $0.24 during midday trading on Thursday, reaching $19.49. The company had a trading volume of 652,526 shares, compared to its average volume of 1,330,752. InMode Ltd. has a one year low of $14.87 and a one year high of $26.80. The stock has a market capitalization of $1.64 billion, a P/E ratio of 10.54 and a beta of 2.15. The stock's fifty day moving average price is $17.53 and its 200-day moving average price is $17.49.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.